Single Dose
Therapeutics
Vision
We envision a future where psychiatric medicine moves beyond symptom management to curative therapies, replacing lifelong treatments with short-term interventions that achieve durable improvements in mental health outcomes.
Mission
Single Dose Therapeutics is dedicated to improving mental health care by developing short-regimen neuroplastogens that enhance psychological resilience. Our mission is to advance these pharmacotherapies through rigorous research and clinical trials, ensuring they become accessible and effective treatment options for psychiatric conditions with unmet needs and those that currently require chronic treatment. We aim to provide innovative therapeutic options that support lasting mental well-being.
In Development
SD-A001 is a drug candidate currently in the preclinical stage of development as a potential pharmacotherapy for conditions characterized by maladaptive learning. It is being evaluated for its potential to initiate neuroadaptive processes that promote allostasis in key neural circuits involved in learning and behavioral regulation. Ongoing research suggests SD-A001 may enhance neuroplasticity without inducing psychotomimetic effects. The unique pharmacological profile of SD-A001 offers a novel approach to facilitate extinction of persistent maladaptive associations that can impair emotional, cognitive, and behavioral flexibility.
Single Dose Therapeutics was founded on the premise that innovative solutions to complex medical challenges emerge at the intersection of disciplines, where openness to different perspectives and strong scientific foundations drive the discovery of transformative treatments. My background in pharmaceutics, pharmaceutical engineering, and translational development has shaped a career dedicated to bridging the gap between scientific discovery and real-world medical impact. This perspective led to the identification of SD-A001, a drug candidate distinguished by its capacity to initiate neuroadaptive processes. It is being evaluated as a potential treatment for substance use disorders and refractory psychiatric conditions that remain underserved by conventional approaches. Single Dose Therapeutics is advancing SD-A001 toward clinical trials while building strategic partnerships with domain experts and industry leaders to accelerate development.
Founder's Note
Davin Rautiola
Single Dose Therapeutics
446 Old County Rd, Ste 100-386
Pacifica, CA 94044
650-665-9663